Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hepatic encephalopathy markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.9 Billion by 2034, exhibiting a growth rate (CAGR) of 5.1% during 2024-2034.
The hepatic encephalopathy market has been comprehensively analyzed in IMARC's new report titled "Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatic encephalopathy is a neurological condition that occurs as a result of liver dysfunction or failure. The liver plays a substantial role in removing waste products from the blood, and when it becomes impaired, these toxins can accumulate in the bloodstream and affect the brain. The most common indications associated with this disorder include irritability, mood swings, agitation, confusion, depression, memory loss, disorientation, sleep disturbances, slurred speech, poor coordination between movements, tremors, muscle stiffness, a sweet, musty odor on the breath, etc. Individuals suffering from the ailment may also experience yellowing of the eyes and skin due to the liver's impaired ability to process bilirubin. Hepatic encephalopathy is usually diagnosed based on clinical symptoms, neurological examination findings, and laboratory tests that show elevated ammonia levels in the blood. The healthcare professional may also perform several diagnostic procedures, like ultrasounds, computed tomography (CT) scans, magnetic resonance imaging, etc., to assess the structure and function of the liver as well as detect any irregularities that may be contributing to the underlying indications.
The increasing cases of liver tissue scarring due to chronic hepatitis B or C infection, excessive alcohol consumption, genetic and metabolic disorders, etc., are primarily driving the hepatic encephalopathy market. In addition to this, the rising incidences of portal hypertension, which causes blood to bypass the liver, leading to the accumulation of toxic substances in the bloodstream that can affect brain function, are creating a positive outlook for the market. Moreover, the widespread adoption of effective antibiotics, such as neomycin and rifaximin, to treat recurrent disease conditions is further acting as another significant growth-inducing factor. These therapeutic agents work by selectively suppressing the spread of harmful bacteria in the gut while preserving beneficial gut flora to alleviate the symptoms of the illness. Apart from this, the escalating application of ornithine phenylacetate therapy, since it stimulates the synthesis of glutamine in muscle tissue to aid in the removal of ammonia via alternative pathways, thereby stabilizing cognitive function and improving mental status in patients, is expected to drive the hepatic encephalopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hepatic encephalopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic encephalopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic encephalopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatic encephalopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatic encephalopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatic encephalopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatic encephalopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatic encephalopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatic encephalopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with hepatic encephalopathy across the seven major markets?
What is the size of the hepatic encephalopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatic encephalopathy?
What will be the growth rate of patients across the seven major markets?
Hepatic Encephalopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatic encephalopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic encephalopathy market?
What are the key regulatory events related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by status related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by phase related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by route of administration related to the hepatic encephalopathy market?
The hepatic encephalopathy market has been comprehensively analyzed in IMARC's new report titled "Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatic encephalopathy is a neurological condition that occurs as a result of liver dysfunction or failure. The liver plays a substantial role in removing waste products from the blood, and when it becomes impaired, these toxins can accumulate in the bloodstream and affect the brain. The most common indications associated with this disorder include irritability, mood swings, agitation, confusion, depression, memory loss, disorientation, sleep disturbances, slurred speech, poor coordination between movements, tremors, muscle stiffness, a sweet, musty odor on the breath, etc. Individuals suffering from the ailment may also experience yellowing of the eyes and skin due to the liver's impaired ability to process bilirubin. Hepatic encephalopathy is usually diagnosed based on clinical symptoms, neurological examination findings, and laboratory tests that show elevated ammonia levels in the blood. The healthcare professional may also perform several diagnostic procedures, like ultrasounds, computed tomography (CT) scans, magnetic resonance imaging, etc., to assess the structure and function of the liver as well as detect any irregularities that may be contributing to the underlying indications.
The increasing cases of liver tissue scarring due to chronic hepatitis B or C infection, excessive alcohol consumption, genetic and metabolic disorders, etc., are primarily driving the hepatic encephalopathy market. In addition to this, the rising incidences of portal hypertension, which causes blood to bypass the liver, leading to the accumulation of toxic substances in the bloodstream that can affect brain function, are creating a positive outlook for the market. Moreover, the widespread adoption of effective antibiotics, such as neomycin and rifaximin, to treat recurrent disease conditions is further acting as another significant growth-inducing factor. These therapeutic agents work by selectively suppressing the spread of harmful bacteria in the gut while preserving beneficial gut flora to alleviate the symptoms of the illness. Apart from this, the escalating application of ornithine phenylacetate therapy, since it stimulates the synthesis of glutamine in muscle tissue to aid in the removal of ammonia via alternative pathways, thereby stabilizing cognitive function and improving mental status in patients, is expected to drive the hepatic encephalopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hepatic encephalopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatic encephalopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatic encephalopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatic encephalopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatic encephalopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatic encephalopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatic encephalopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatic encephalopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatic encephalopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of hepatic encephalopathy by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with hepatic encephalopathy across the seven major markets?
What is the size of the hepatic encephalopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatic encephalopathy?
What will be the growth rate of patients across the seven major markets?
Hepatic Encephalopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatic encephalopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatic encephalopathy market?
What are the key regulatory events related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by status related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by phase related to the hepatic encephalopathy market?
What is the structure of clinical trial landscape by route of administration related to the hepatic encephalopathy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATIC ENCEPHALOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEPATIC ENCEPHALOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATIC ENCEPHALOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HEPATIC ENCEPHALOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATIC ENCEPHALOPATHY - UNMET NEEDS
10 HEPATIC ENCEPHALOPATHY - KEY ENDPOINTS OF TREATMENT
11 HEPATIC ENCEPHALOPATHY - MARKETED PRODUCTS
11.1 List of Hepatic Encephalopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Xifaxan (Rifaximin) - Alfasigma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEPATIC ENCEPHALOPATHY - PIPELINE DRUGS
12.1 List of Hepatic Encephalopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Ornithine phenylacetate - Ocera Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RBX 7455 - Ochsner Health
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VE 303 - Vedanta Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATIC ENCEPHALOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEPATIC ENCEPHALOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEPATIC ENCEPHALOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hepatic Encephalopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hepatic Encephalopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hepatic Encephalopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hepatic Encephalopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hepatic Encephalopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hepatic Encephalopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hepatic Encephalopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hepatic Encephalopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hepatic Encephalopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hepatic Encephalopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hepatic Encephalopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hepatic Encephalopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hepatic Encephalopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hepatic Encephalopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hepatic Encephalopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hepatic Encephalopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hepatic Encephalopathy - Access and Reimbursement Overview
16 HEPATIC ENCEPHALOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEPATIC ENCEPHALOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEPATIC ENCEPHALOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATIC ENCEPHALOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEPATIC ENCEPHALOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATIC ENCEPHALOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HEPATIC ENCEPHALOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATIC ENCEPHALOPATHY - UNMET NEEDS
10 HEPATIC ENCEPHALOPATHY - KEY ENDPOINTS OF TREATMENT
11 HEPATIC ENCEPHALOPATHY - MARKETED PRODUCTS
11.1 List of Hepatic Encephalopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Xifaxan (Rifaximin) - Alfasigma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEPATIC ENCEPHALOPATHY - PIPELINE DRUGS
12.1 List of Hepatic Encephalopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Ornithine phenylacetate - Ocera Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RBX 7455 - Ochsner Health
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 VE 303 - Vedanta Biosciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATIC ENCEPHALOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEPATIC ENCEPHALOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEPATIC ENCEPHALOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hepatic Encephalopathy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hepatic Encephalopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hepatic Encephalopathy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hepatic Encephalopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hepatic Encephalopathy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hepatic Encephalopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hepatic Encephalopathy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hepatic Encephalopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hepatic Encephalopathy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hepatic Encephalopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hepatic Encephalopathy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hepatic Encephalopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hepatic Encephalopathy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hepatic Encephalopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hepatic Encephalopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hepatic Encephalopathy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hepatic Encephalopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hepatic Encephalopathy - Access and Reimbursement Overview
16 HEPATIC ENCEPHALOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEPATIC ENCEPHALOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEPATIC ENCEPHALOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
